449 related articles for article (PubMed ID: 7699439)
1. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
4. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
[TBL] [Abstract][Full Text] [Related]
6. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
9. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Anthony LB; Woltering EA; Espenan GD; Cronin MD; Maloney TJ; McCarthy KE
Semin Nucl Med; 2002 Apr; 32(2):123-32. PubMed ID: 11965607
[TBL] [Abstract][Full Text] [Related]
10. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
11. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
12. [Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors].
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Benning R; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Nuklearmedizin; 1993 Dec; 32(6):299-305. PubMed ID: 7905200
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging for neuroendocrine tumors.
de Herder WW; Kwekkeboom DJ; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
Pituitary; 2006; 9(3):243-8. PubMed ID: 17001462
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
17. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
18. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
[TBL] [Abstract][Full Text] [Related]
19. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
